Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Volume 31, Issue 15
  5. Article
Volume 31, Issue 15
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Background

In vascular tissue, macrophages and inflammatory cells produce the enzyme lipoprotein-associated phospholipase A2 (Lp-PLA2). Treatment with fibrates decreases Lp-PLA2 levels in individuals with obesity and metabolic syndrome; however, these findings have not been fully clarified.

Objective

The goal of this study was to investigate the possible effects of fibrate therapy on Lp-PLA2 mass and activity through a meta-analysis of clinical trials.

Methods

Web of Science, PubMed, Scopus, Google Scholar, and ClinicalTrials.gov databases were searched using MeSH terms and keywords. Randomized controlled trials (RCT) evaluating the effect of statins on Lp- PLA2 mass and/or activity were included in the meta-analysis. Quantitative data were analyzed using a random-effects model and the generic inverse variance method.

Results

The meta-analysis of 10 clinical trials indicated that fibrate treatment has no significant effect on Lp- PLA2 mass (fibrate placebo/nothing = WMD: -3.29 ng/ml, 95% CI: -21.35, 14.78, 0.72; fibrate active control = WMD: -1.08 ng/ml, 95% CI: -51.38, 49.22, 0.97); Lp-PLA2 activity (fibrate active control = WMD: 0.84 nmol/ml/min, 95% CI: -0.17, 1.84, 0.10); HDL-LpPLA2 activity (fibrate active control = WMD: 0.77 nmol/ml/min, 95% CI: -0.33, 1.88, 0.17); and secretory PLA2 (fibrate active control = WMD: 0.37 ng/ml, 95% CI: -1.22, 1.97, 0.65). Also, the results of the sensitivity analysis were robust for all these parameters.

Conclusion

In conclusion, fibrate therapy did not reduce the mass and activity of Lp-PLA2.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128345231240925095400
2025-01-13
2025-05-25

  • From This Site

    /content/journals/cpd/10.2174/0113816128345231240925095400
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TellisC.C. TselepisA.D. Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.Biochim. Biophys. Acta Mol. Cell Biol. Lipids20091791532733810.1016/j.bbalip.2009.02.01519272461
     [Google Scholar]
  2. CaslakeM.J. PackardC.J. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.Nat. Clin. Pract. Cardiovasc. Med.200521052953510.1038/ncpcardio032116186851
     [Google Scholar]
  3. MacPheeC.H. MooresK.E. BoydH.F. DhanakD. IfeR.J. LeachC.A. LeakeD.S. MillinerK.J. PattersonR.A. SucklingK.E. TewD.G. HickeyD.M.B. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: Use of a novel inhibitor.Biochem. J.1999338247948710.1042/bj338047910024526
     [Google Scholar]
  4. RosensonR.S. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.Am. Heart J.20081553499.e9499.e1610.1016/j.ahj.2007.12.01218294485
     [Google Scholar]
  5. KurniawanL.B. RampoH. SorayaG.V. AdnanE. EsaT. WidaningsihY. BahrunU. ArifM. Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 diabetes mellitus patients.Obes. Med.20212210031810.1016/j.obmed.2021.100318
     [Google Scholar]
  6. JackischL. KumsaiyaiW. MooreJ.D. Al-DaghriN. KyrouI. BarberT.M. RandevaH. KumarS. TripathiG. McTernanP.G. Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.Diabetologia20186151155116610.1007/s00125‑018‑4558‑629427237
     [Google Scholar]
  7. ViraniS.S. The fibrates story - A tepid end to a PROMINENT drug.N. Engl. J. Med.2022387211991199210.1056/NEJMe221320836342123
     [Google Scholar]
  8. KimN.H. KimS.G. Fibrates revisited: Potential role in cardiovascular risk reduction.Diabetes Metab. J.202044221322110.4093/dmj.2020.000132347023
     [Google Scholar]
  9. SchoonjansK. WatanabeM. SuzukiH. MahfoudiA. KreyG. WahliW. GrimaldiP. StaelsB. YamamotoT. AuwerxJ. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter.J. Biol. Chem.199527033192691927610.1074/jbc.270.33.192697642600
     [Google Scholar]
  10. Seth LoombaR. AroraR. Fibrates: Where are we now?Ther. Adv. Cardiovasc. Dis.200931919610.1177/175394470809628119144670
     [Google Scholar]
  11. OkopieńB. BuldakL. BołdysA. Fibrates in the management of atherogenic dyslipidemia.Expert Rev. Cardiovasc. Ther.2017151291392110.1080/14779072.2017.140841029183206
     [Google Scholar]
  12. MarxN. SukhovaG.K. CollinsT. LibbyP. PlutzkyJ. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.Circulation199999243125313110.1161/01.CIR.99.24.312510377075
     [Google Scholar]
  13. MuhlesteinJ.B. MayH.T. JensenJ.R. HorneB.D. LanmanR.B. LavasaniF. WolfertR.L. PearsonR.R. YannicelliH.D. AndersonJ.L. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.J. Am. Coll. Cardiol.200648239640110.1016/j.jacc.2006.05.00916843192
     [Google Scholar]
  14. FilippatosT.D. GaziI.F. LiberopoulosE.N. AthyrosV.G. ElisafM.S. TselepisA.D. KiortsisD.N. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.Atherosclerosis2007193242843710.1016/j.atherosclerosis.2006.07.01016911813
     [Google Scholar]
  15. AgouridisA.P. TsimihodimosV. FilippatosT.D. DimitriouA.A. TellisC.C. ElisafM.S. MikhailidisD.P. TselepisA.D. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.Expert Opin. Pharmacother.201112172605261110.1517/14656566.2011.59138321714585
     [Google Scholar]
  16. RobinsS.J. CollinsD. NelsonJ.J. BloomfieldH.E. AsztalosB.F. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: The veterans affairs HDL intervention trial.Arterioscler. Thromb. Vasc. Biol.20082861172117810.1161/ATVBAHA.107.16073918356553
     [Google Scholar]
  17. ConstantinidesA. de VriesR. van LeeuwenJ.J.J. GautierT. van PeltL.J. TselepisA.D. LagrostL. DullaartR.P.F. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A2 mass in type 2 diabetes mellitus: Relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.Eur. J. Intern. Med.201223763363810.1016/j.ejim.2012.05.00822902096
     [Google Scholar]
  18. ThompsonA. GaoP. OrfeiL. WatsonS. Di AngelantonioE. KaptogeS. BallantyneC. CannonC.P. CriquiM. CushmanM. HofmanA. PackardC. ThompsonS.G. CollinsR. DaneshJ. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies.Lancet201037597251536154410.1016/S0140‑6736(10)60319‑420435228
     [Google Scholar]
  19. MoherD. ShamseerL. ClarkeM. GhersiD. LiberatiA. PetticrewM. ShekelleP. StewartL.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Syst. Rev.201541110.1186/2046‑4053‑4‑125554246
     [Google Scholar]
  20. SterneJ.A.C. SavovićJ. PageM.J. ElbersR.G. BlencoweN.S. BoutronI. CatesC.J. ChengH.Y. CorbettM.S. EldridgeS.M. EmbersonJ.R. HernánM.A. HopewellS. HróbjartssonA. JunqueiraD.R. JüniP. KirkhamJ.J. LassersonT. LiT. McAleenanA. ReevesB.C. ShepperdS. ShrierI. StewartL.A. TillingK. WhiteI.R. WhitingP.F. HigginsJ.P.T. RoB 2: A revised tool for assessing risk of bias in randomised trials.BMJ2019366l489810.1136/bmj.l489831462531
     [Google Scholar]
  21. WanX. WangW. LiuJ. TongT. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.BMC Med. Res. Methodol.201414113510.1186/1471‑2288‑14‑13525524443
     [Google Scholar]
  22. HozoS.P. DjulbegovicB. HozoI. Estimating the mean and variance from the median, range, and the size of a sample.BMC Med. Res. Methodol.2005511310.1186/1471‑2288‑5‑1315840177
     [Google Scholar]
  23. Simental-MendíaL.E. Sánchez-GarcíaA. Linden-TorresE. Simental-MendíaM. Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials.Diabetes Res. Clin. Pract.202117710889910.1016/j.diabres.2021.10889934098057
     [Google Scholar]
  24. SaougosV.G. TambakiA.P. KalogirouM. KostapanosM. GaziI.F. WolfertR.L. ElisafM. TselepisA.D. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.Arterioscler. Thromb. Vasc. Biol.200727102236224310.1161/ATVBAHA.107.14728017656665
     [Google Scholar]
  25. WootenJ.S. NambiP. GillardB.K. PownallH.J. CorazaI. ScottL.W. NambiV. BallantyneC.M. BalasubramanyamA. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.Med. Sci. Sports Exerc.20134561043105010.1249/MSS.0b013e318284396123299761
     [Google Scholar]
  26. WägnerA.M. Sánchez-QuesadaJ.L. BenítezS. BancellsC. Ordóñez-LlanosJ. PérezA. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.Diabetes Res. Clin. Pract.2011931e25e2810.1016/j.diabres.2011.03.00921440948
     [Google Scholar]
  27. TsunodaF. AsztalosI.B. HorvathK.V. SteinerG. SchaeferE.J. AsztalosB.F. Fenofibrate, HDL, and cardiovascular disease in type-2 diabetes: The DAIS trial.Atherosclerosis2016247353910.1016/j.atherosclerosis.2016.01.02826854974
     [Google Scholar]
  28. KeiA. LiberopoulosE. TellisC. ElisafM. TselepisA. Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions.Lipids2013481095796510.1007/s11745‑013‑3826‑y23949918
     [Google Scholar]
  29. HogueJ.C. LamarcheB. TremblayA.J. BergeronJ. GagnéC. CoutureP. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.Metabolism200857338038610.1016/j.metabol.2007.10.01418249211
     [Google Scholar]
  30. HiukkaA. WesterbackaJ. LeinonenE.S. WatanabeH. WiklundO. HultenL.M. SalonenJ.T. TuomainenT.P. Yki-JärvinenH. KeechA.C. TaskinenM.R. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.J. Am. Coll. Cardiol.200852252190219710.1016/j.jacc.2008.09.04919095138
     [Google Scholar]
  31. JuH.B. ZhangF.X. WangS. SongJ. CuiT. LiL.F. ZhangH.Y. Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients.Medicine (Baltimore)20179631e767110.1097/MD.000000000000767128767589
     [Google Scholar]
  32. KujiraokaT. IwasakiT. IshiharaM. ItoM. NaganoM. KawaguchiA. TakahashiS. IshiJ. TsujiM. EgashiraT. StepanovaI.P. MillerN.E. HattoriH. Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus.J. Lipid Res.200344102006201410.1194/jlr.D300021‑JLR20012867534
     [Google Scholar]
  33. LalloyerF. StaelsB. Fibrates, glitazones, and peroxisome proliferator-activated receptors.Arterioscler. Thromb. Vasc. Biol.201030589489910.1161/ATVBAHA.108.17968920393155
     [Google Scholar]
  34. TsimihodimosV. KakafikaA. TambakiA.P. BairaktariE. ChapmanM.J. ElisafM. TselepisA.D. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.J. Lipid Res.200344592793410.1194/jlr.M200452‑JLR20012611907
     [Google Scholar]
  35. JakobT. NordmannA.J. SchandelmaierS. Ferreira-GonzálezI. BrielM. Fibrates for primary prevention of cardiovascular disease events.Cochrane Libr.201620173CD00975310.1002/14651858.CD009753.pub227849333
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128345231240925095400
Loading
Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials
Curr. Pharm. Des. 31, 1205 (2025); https://doi.org/10.2174/0113816128345231240925095400
/content/journals/cpd/10.2174/0113816128345231240925095400
/content/journals/cpd/10.2174/0113816128345231240925095400
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Fibrates; HDL-LpPLA2; inflammatory cells; lipoprotein-associated phospholipase A2; macrophages; metabolic syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test